Who says Seeking Alpha doesn't highlight penny sto
Post# of 7769
Posted On: 04/12/2014 9:18:43 AM
Who says Seeking Alpha doesn't highlight penny stocks. Below is a summary of a pharma penny stock that deserves to have CHP on their IHub board. What a contrast to SCRC a penny stock company producing revenues, soon to be cash flow positive and debt free, a real business with revenue streams, and definitely a bright, bright, future.
Rich Pharmaceuticals: Why This Illegal Spam Promotion Could Be Set To Drop
Apr. 11, 2014 2:05 PM ET | 7 comments | About: RCHA
Summary
•There is illegal spam stock promotion being sent out.
•There are 300,000,000 free trading shares in insiders hands.
•They are even sending spam to government emails (not smart).
Rich Pharmaceuticals, Inc.(OTCQB:RCHA) is a name that I believe is currently the target of an illegal spam penny-stock promotion scheme. It is my view that the stock's intrinsic value is somewhere near $0, and it is with conviction that I recommend that any investors currently in the name sell the entirety of their stakes immediately. Today's morning weakness could be a signal that the dump is near. I also believe that Rich Pharmaceuticals, Inc. is a stock definitely worth shorting. My track record of identifying and publicly exposing such highly overvalued equities is excellent:
Company Background
Rich Pharmaceuticals, Inc. (RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate which is known as PD-616 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at richpharmaceuticals.com.
Little Revenue. Debts. No Business. Bright Future?
As is usually the case with these types of hyped up scams, it takes only one quick glance at the balance sheet to realize that the $142M market capitalization that this equity commands is beyond ludicrous. With no shot of any drugs being approved until 2016. That is expecting they pass all trials, which no one knows if they even will. It's my suspicion that the purpose of this company is not to succeed but to sell stock. The recent volume is due to overly bullish promotional spam.
GO SCRC!!!
Rich Pharmaceuticals: Why This Illegal Spam Promotion Could Be Set To Drop
Apr. 11, 2014 2:05 PM ET | 7 comments | About: RCHA
Summary
•There is illegal spam stock promotion being sent out.
•There are 300,000,000 free trading shares in insiders hands.
•They are even sending spam to government emails (not smart).
Rich Pharmaceuticals, Inc.(OTCQB:RCHA) is a name that I believe is currently the target of an illegal spam penny-stock promotion scheme. It is my view that the stock's intrinsic value is somewhere near $0, and it is with conviction that I recommend that any investors currently in the name sell the entirety of their stakes immediately. Today's morning weakness could be a signal that the dump is near. I also believe that Rich Pharmaceuticals, Inc. is a stock definitely worth shorting. My track record of identifying and publicly exposing such highly overvalued equities is excellent:
Company Background
Rich Pharmaceuticals, Inc. (RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate which is known as PD-616 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at richpharmaceuticals.com.
Little Revenue. Debts. No Business. Bright Future?
As is usually the case with these types of hyped up scams, it takes only one quick glance at the balance sheet to realize that the $142M market capitalization that this equity commands is beyond ludicrous. With no shot of any drugs being approved until 2016. That is expecting they pass all trials, which no one knows if they even will. It's my suspicion that the purpose of this company is not to succeed but to sell stock. The recent volume is due to overly bullish promotional spam.
GO SCRC!!!
(0)
(0)